https://www.mbcalliance.org/wp-content/uploads/2023.02.06FORCE63c7f70f95f29.jpg 667 1000 MBCA https://www.mbcalliance.org/wp-content/uploads/mbca-logo.png MBCA2023-02-03 09:18:242023-02-07 19:53:13Trodelvy benefits people with advanced hormone-positive metastatic breast cancer
Trodelvy benefits people with advanced hormone-positive metastatic breast cancer
The study TROPiCS-2 showed that the drug Trodelvy (sacituzumab govitecan) improved progression-free survival when compared to chemotherapy in people with advanced metastatic ER/PR-positive, HER2-negative breast cancer who have few other treatment options. This drug does not yet have FDA approval for use in the hormone-positive setting. (Posted 1/18/23) Update: On 02/03/2023 the FDA approved approved Trodelvy for patients with locally advanced or metastatic breast cancer who have received hormonal therapy and at least two other types of treatment in the metastatic setting.